Clinical Trials List
2021-04-01 - 2024-05-14
Phase II
Recruiting4
ICD-10M32.0
Drug-induced systemic lupus erythematosus
ICD-10M32.10
Systemic lupus erythematosus, organ or system involvement unspecified
ICD-10M32.11
Endocarditis in systemic lupus erythematosus
ICD-10M32.12
Pericarditis in systemic lupus erythematosus
ICD-10M32.13
Lung involvement in systemic lupus erythematosus
ICD-10M32.14
Glomerular disease in systemic lupus erythematosus
ICD-10M32.15
Tubulo-interstitial nephropathy in systemic lupus erythematosus
ICD-10M32.19
Other organ or system involvement in systemic lupus erythematosus
ICD-10M32.8
Other forms of systemic lupus erythematosus
ICD-10M32.9
Systemic lupus erythematosus, unspecified
ICD-9710.0
Systemic lupus erythematosus
-
Trial Applicant
IQVIA RDS Taiwan Ltd.
-
Sponsor
-
Trial scale
Multi-Regional Multi-Center
-
Update
2025/08/20
Investigators and Locations
Co-Principal Investigator
- CHENG-HAN WU Division of General Internal Medicine
- SONG-CHOU HSIEH Division of General Internal Medicine
- 郭佑民 Division of General Internal Medicine
- 呂政勳 Division of General Internal Medicine
- KO-JEN LI Division of General Internal Medicine
The Actual Total Number of Participants Enrolled
0 Recruiting
The Actual Total Number of Participants Enrolled
0 Recruiting
The Actual Total Number of Participants Enrolled
0 Recruiting
Co-Principal Investigator
- HSIN-HUA CHEN 無
- 曾智偉 Division of Rheumatology
- 謝祖怡 無
- 洪維廷 無
- 陳彥如 無
- WEN-NAN HUANG 無
- Yi-Ming Chen 無
- 吳沂達 無
- 謝佳偉 無
- 林靖才 無
- 廖育婉 無
The Actual Total Number of Participants Enrolled
0 Recruiting
Condition/Disease
Objectives
Test Drug
Active Ingredient
Dosage Form
Dosage
Endpoints
Inclution Criteria
The Estimated Number of Participants
-
Taiwan
14 participants
-
Global
320 participants
